Tel Aviv - Delayed Quote ILA

InterCure Ltd. (INCR.TA)

585.00

-19.50

(-3.23%)

At close: January 30 at 5:24:48 PM GMT+2

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), is pleased to announce that further to the Company's prior reports regarding the war-related damages and the reconstruction efforts of its facility in Kibbutz Nir Oz, the Company was successful in obtaining funding commitments of NIS 66 million (approximately USD 18.2M), which may increase to NIS 107 million (approximately USD 29.8M).

PR Newswire last month

INCR
+1.82%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector SNDL acquired Indiva in efforts to strengthen position in cannabis edibles market. Ascend Wellness overhauled leadership amid financial struggles. Avicanna reduced debt with $2M private placement funds. InterCure reported a break-even first half of 2024 despite Israel-Hamas war disruptions. Key Takeaways; Psychedelic Sector Awakn announced a breakthrough in aminoindane pre-clinical program. […]

Market Exclusive 4 months ago

SNDL

AWKNF

INCR
+1.82%
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure’s 16th and 17th consecutive quarter of profitability2.Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensation from the Isra

GlobeNewswire 4 months ago

INCR
+1.82%
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

NEW YORK & HERZLIYA, Israel, August 28, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across

Business Wire 5 months ago

INCR
+1.82%
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

NEW YORK & HERZLIYA, Israel, May 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City.

Business Wire 8 months ago

INCR
+1.82%
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

NEW YORK & HERZLIYA, Israel, May 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.

Business Wire 8 months ago

INCR
+1.82%
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

NEW YORK & HERZLIYA, Israel, April 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.

Business Wire 9 months ago

INCR
+1.82%
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

NEW YORK & HERZLIYA, Israel, March 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.

Business Wire 10 months ago

INCR
+1.82%
InterCure Provides an Update Regarding Nir Oz Facility

NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additi

GlobeNewswire 11 months ago

INCR
+1.82%

Performance Overview

Return	INCR.TA	S&P 500
YTD	+2.69%	+3.22%
1-Year	+29.63%	+23.80%
3-Year	-69.52%	+37.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InterCure Ltd. (INCR.TA)

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

InterCure Provides an Update Regarding Nir Oz Facility

Performance Overview